Ei­sai launch­es biotech di­vi­sion in Mass­a­chu­setts aimed at Alzheimer’s, I/O and au­toim­mune dis­eases

Ei­sai is tack­ling Alzheimer’s, au­toim­mune dis­eases and the tu­mor mi­croen­vi­ron­ment with a new “biotech-like” re­search unit in An­dover, MA that has al­ready brought to­geth­er 90 re­searchers whose ex­per­tise cuts across a va­ri­ety of dis­ci­plines.

The new unit has been dubbed the Ei­sai An­dover in­no­v­a­tive Med­i­cines (AiM) In­sti­tute, which is op­er­at­ing in a 220,000-square foot fa­cil­i­ty. And it’s mak­ing ex­ter­nal col­lab­o­ra­tions with the ex­ten­sive sci­en­tif­ic and biotech com­mu­ni­ty in the big Boston hub a top pri­or­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER